Aratana Therapeutics to Attend North American Veterinary Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Aratana Therapeutics (PETX) Shares Decline Following Update on ENTYCE Availability
February 6, 2017 10:59 AM ESTAratana Therapeutics (NASDAQ: PETX) declined Monday after saying in an SEC filing that ENTYCE (capromorelin oral solution) won't be commercially available until late-2017.
From the filing:
In connection with the 2017 North American Veterinary Conference in Orlando, Florida, on February 6, 2017, Aratana Therapeutics, Inc. (the Company) provided certain business updates.
The Company now anticipates that ENTYCE® (capromorelin oral solution) will... More